JP7220986B6 - 治療効果のある化合物及びその使用方法 - Google Patents

治療効果のある化合物及びその使用方法 Download PDF

Info

Publication number
JP7220986B6
JP7220986B6 JP2017541075A JP2017541075A JP7220986B6 JP 7220986 B6 JP7220986 B6 JP 7220986B6 JP 2017541075 A JP2017541075 A JP 2017541075A JP 2017541075 A JP2017541075 A JP 2017541075A JP 7220986 B6 JP7220986 B6 JP 7220986B6
Authority
JP
Japan
Prior art keywords
compound
day
idh2
crystalline form
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017541075A
Other languages
English (en)
Japanese (ja)
Other versions
JP7220986B2 (ja
JP2018504429A5 (https=
JP2018504429A (ja
Inventor
クルーゲ ステファン
Original Assignee
アジオス ファーマシューティカルズ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アジオス ファーマシューティカルズ， インコーポレイテッド filed Critical アジオス ファーマシューティカルズ， インコーポレイテッド
Publication of JP2018504429A publication Critical patent/JP2018504429A/ja
Publication of JP2018504429A5 publication Critical patent/JP2018504429A5/ja
Priority to JP2022175208A priority Critical patent/JP2023011792A/ja
Publication of JP7220986B2 publication Critical patent/JP7220986B2/ja
Application granted granted Critical
Publication of JP7220986B6 publication Critical patent/JP7220986B6/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N23/00—Investigating or analysing materials by the use of wave or particle radiation, e.g. X-rays or neutrons, not covered by groups G01N3/00 – G01N17/00, G01N21/00 or G01N22/00
    • G01N23/20—Investigating or analysing materials by the use of wave or particle radiation, e.g. X-rays or neutrons, not covered by groups G01N3/00 – G01N17/00, G01N21/00 or G01N22/00 by using diffraction of the radiation by the materials, e.g. for investigating crystal structure; by using scattering of the radiation by the materials, e.g. for investigating non-crystalline materials; by using reflection of the radiation by the materials
    • G01N23/20075—Investigating or analysing materials by the use of wave or particle radiation, e.g. X-rays or neutrons, not covered by groups G01N3/00 – G01N17/00, G01N21/00 or G01N22/00 by using diffraction of the radiation by the materials, e.g. for investigating crystal structure; by using scattering of the radiation by the materials, e.g. for investigating non-crystalline materials; by using reflection of the radiation by the materials by measuring interferences of X-rays, e.g. Borrmann effect
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N25/00—Investigating or analyzing materials by the use of thermal means
    • G01N25/20—Investigating or analyzing materials by the use of thermal means by investigating the development of heat, i.e. calorimetry, e.g. by measuring specific heat, by measuring thermal conductivity
    • G01N25/48—Investigating or analyzing materials by the use of thermal means by investigating the development of heat, i.e. calorimetry, e.g. by measuring specific heat, by measuring thermal conductivity on solution, sorption, or a chemical reaction not involving combustion or catalytic oxidation
    • G01N25/4846—Investigating or analyzing materials by the use of thermal means by investigating the development of heat, i.e. calorimetry, e.g. by measuring specific heat, by measuring thermal conductivity on solution, sorption, or a chemical reaction not involving combustion or catalytic oxidation for a motionless, e.g. solid sample
    • G01N25/4866—Investigating or analyzing materials by the use of thermal means by investigating the development of heat, i.e. calorimetry, e.g. by measuring specific heat, by measuring thermal conductivity on solution, sorption, or a chemical reaction not involving combustion or catalytic oxidation for a motionless, e.g. solid sample by using a differential method

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2017541075A 2015-02-04 2016-02-03 治療効果のある化合物及びその使用方法 Active JP7220986B6 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022175208A JP2023011792A (ja) 2015-02-04 2022-11-01 治療効果のある化合物及びその使用方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562112127P 2015-02-04 2015-02-04
US62/112,127 2015-02-04
PCT/US2016/016335 WO2016126798A1 (en) 2015-02-04 2016-02-03 Therapeutically active compounds and their methods of use

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2020180152A Division JP2021038227A (ja) 2015-02-04 2020-10-28 治療効果のある化合物及びその使用方法
JP2022175208A Division JP2023011792A (ja) 2015-02-04 2022-11-01 治療効果のある化合物及びその使用方法

Publications (4)

Publication Number Publication Date
JP2018504429A JP2018504429A (ja) 2018-02-15
JP2018504429A5 JP2018504429A5 (https=) 2019-03-14
JP7220986B2 JP7220986B2 (ja) 2023-02-13
JP7220986B6 true JP7220986B6 (ja) 2024-02-08

Family

ID=55640843

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2017541075A Active JP7220986B6 (ja) 2015-02-04 2016-02-03 治療効果のある化合物及びその使用方法
JP2020180152A Pending JP2021038227A (ja) 2015-02-04 2020-10-28 治療効果のある化合物及びその使用方法
JP2022175208A Pending JP2023011792A (ja) 2015-02-04 2022-11-01 治療効果のある化合物及びその使用方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2020180152A Pending JP2021038227A (ja) 2015-02-04 2020-10-28 治療効果のある化合物及びその使用方法
JP2022175208A Pending JP2023011792A (ja) 2015-02-04 2022-11-01 治療効果のある化合物及びその使用方法

Country Status (8)

Country Link
US (2) US10201543B2 (https=)
EP (1) EP3253746A1 (https=)
JP (3) JP7220986B6 (https=)
KR (1) KR102628370B1 (https=)
CN (1) CN107531675A (https=)
CA (1) CA2975506A1 (https=)
IL (1) IL253796A0 (https=)
WO (1) WO2016126798A1 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI666208B (zh) 2013-08-02 2019-07-21 美商阿吉斯藥品有限公司 治療活性化合物及其使用方法（三）
AU2015324158A1 (en) 2014-09-29 2017-04-13 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
CN107531675A (zh) 2015-02-04 2018-01-02 安吉奥斯医药品有限公司 治疗活性化合物及其使用方法
CA2993615A1 (en) 2015-08-05 2017-02-09 Agios Pharmaceuticals, Inc. Methods of preparing 6-(aryl or heteroaryl)-1,3,5-triazine-2,4-diols and 6-(aryl or heteroaryl)-1,3,5-triazine-2,4-diamines
US10695352B2 (en) 2015-10-15 2020-06-30 Celgene Corporation Combination therapy for treating malignancies
CN108366980A (zh) 2015-10-15 2018-08-03 安吉奥斯医药品有限公司 用于治疗恶性肿瘤的组合疗法
IL298663A (en) 2015-12-04 2023-01-01 Agios Pharmaceuticals Inc Methods for treating acute myeloid leukemia characterized by the presence of a mutant allele of idh2 and the absence of a mutant allele of nras
ES2912909T3 (es) 2016-02-26 2022-05-30 Celgene Corp Enasidenib para su uso en el tratamiento de la leucemia mieloide aguda recidivante o refractaria
EP3493809B1 (en) 2016-08-03 2023-08-23 Celgene Corporation Enasidenib for treatment of myelodysplastic syndrome
JP7093764B2 (ja) * 2016-08-03 2022-06-30 セルジーン コーポレイション 骨髄異形成症候群の治療方法
MX392941B (es) 2016-09-07 2025-03-24 Celgene Corp Composiciones para comprimidos.
WO2018204787A1 (en) 2017-05-05 2018-11-08 Memorial Sloan Kettering Cancer Center Methods of treatment of myeloproliferative neoplasm
WO2020092894A1 (en) 2018-11-02 2020-05-07 Celgene Corporation Solid forms of 2-methyl-1-[(4-[6-(trifluoromethyl) pyridin-2-yl]-6-{[2-(trifluoromethyl)pyridin-4-yl]amino}-1,3,5-triazin-2-yl) amino]propan-2-ol
WO2020092906A1 (en) 2018-11-02 2020-05-07 Celgene Corporation Co-crystals of 2-methyl-1 -[(4-[6-(trifluoromethyl)pyridin-2-yl]-6-{[2-(trifluoromethyl) pyridin-4-yl]amino}-1,3,5-triazin-2-yl)amino]propan-2-ol, compositions and methods of use thereof
WO2020092915A1 (en) 2018-11-02 2020-05-07 Celgene Corporation Solid dispersions for treatment of cancer
WO2021097160A1 (en) 2019-11-14 2021-05-20 Celgene Corporation Pediatric formulations for treatment of cancer
CN114773320A (zh) * 2022-05-29 2022-07-22 重庆医科大学 1,3,5-三嗪化合物及其制备方法和用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015503571A (ja) 2012-01-06 2015-02-02 アジオス ファーマシューティカルズ， インコーポレイテッド 治療活性化合物およびその使用方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11158073A (ja) * 1997-09-26 1999-06-15 Takeda Chem Ind Ltd アデノシンａ３拮抗剤
MY185687A (en) 2013-07-11 2021-05-30 Agios Pharmaceuticals Inc N,6-bis(aryl or heteroaryl)-1,3,5-triazine-2,4-diamine compounds as idh2 mutants inhibitors for the treatment of cancer
WO2015018060A1 (en) * 2013-08-09 2015-02-12 Agios Pharmaceuticals, Inc. Crystalline forms of therapeutically active compounds and use thereof
TWI666208B (zh) 2013-08-02 2019-07-21 美商阿吉斯藥品有限公司 治療活性化合物及其使用方法（三）
AU2015324158A1 (en) 2014-09-29 2017-04-13 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
CN107531675A (zh) * 2015-02-04 2018-01-02 安吉奥斯医药品有限公司 治疗活性化合物及其使用方法
CA2993615A1 (en) 2015-08-05 2017-02-09 Agios Pharmaceuticals, Inc. Methods of preparing 6-(aryl or heteroaryl)-1,3,5-triazine-2,4-diols and 6-(aryl or heteroaryl)-1,3,5-triazine-2,4-diamines
CN108366980A (zh) 2015-10-15 2018-08-03 安吉奥斯医药品有限公司 用于治疗恶性肿瘤的组合疗法
IL298663A (en) 2015-12-04 2023-01-01 Agios Pharmaceuticals Inc Methods for treating acute myeloid leukemia characterized by the presence of a mutant allele of idh2 and the absence of a mutant allele of nras
ES2912909T3 (es) 2016-02-26 2022-05-30 Celgene Corp Enasidenib para su uso en el tratamiento de la leucemia mieloide aguda recidivante o refractaria
EP3493809B1 (en) 2016-08-03 2023-08-23 Celgene Corporation Enasidenib for treatment of myelodysplastic syndrome
MX392941B (es) 2016-09-07 2025-03-24 Celgene Corp Composiciones para comprimidos.

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015503571A (ja) 2012-01-06 2015-02-02 アジオス ファーマシューティカルズ， インコーポレイテッド 治療活性化合物およびその使用方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
小嶌隆史，医薬品開発における結晶性選択の効率化を目指して，社団法人日本薬剤学会，薬剤学，２００８年９月１日，Ｖｏｌ．６８，Ｎｏ．５，ｐ．３４４－３４９
平山令明編著，有機化合物結晶作製ハンドブック－原理とノウハウ－，丸善株式会社，２００８，ｐ．１７－２３，３７－４０，４５－５１，５７－６５

Also Published As

Publication number Publication date
US10201543B2 (en) 2019-02-12
JP7220986B2 (ja) 2023-02-13
CN107531675A (zh) 2018-01-02
EP3253746A1 (en) 2017-12-13
US20190117662A1 (en) 2019-04-25
WO2016126798A1 (en) 2016-08-11
KR20170113628A (ko) 2017-10-12
CA2975506A1 (en) 2016-08-11
JP2023011792A (ja) 2023-01-24
US20180028539A1 (en) 2018-02-01
IL253796A0 (en) 2017-09-28
JP2018504429A (ja) 2018-02-15
US10434105B2 (en) 2019-10-08
JP2021038227A (ja) 2021-03-11
KR102628370B1 (ko) 2024-01-24

Similar Documents

Publication Publication Date Title
JP7220986B6 (ja) 治療効果のある化合物及びその使用方法
US20260085059A1 (en) Therapeutically active compounds and their methods of use
KR102316886B1 (ko) 치료학적 활성 화합물 및 이의 사용방법
HK40016190A (en) Therapeutically active compounds and their methods of use
HK40016189A (en) Therapeutically active compounds and their methods of use
HK40016189B (en) Therapeutically active compounds and their methods of use
HK40016900A (en) Therapeutically active compounds and their methods of use
HK40016900B (en) Therapeutically active compounds and their methods of use

Legal Events

Date Code Title Description
A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20190201

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190201

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20191119

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20191121

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200218

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20200218

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20200630

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20201028

C116 Written invitation by the chief administrative judge to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C116

Effective date: 20201110

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20201110

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20201209

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20210413

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20220426

C27C Written answer of applicant after an oral proceeding

Free format text: JAPANESE INTERMEDIATE CODE: C2721

Effective date: 20220712

C13 Notice of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: C13

Effective date: 20220802

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20221004

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221101

C23 Notice of termination of proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C23

Effective date: 20221129

C03 Trial/appeal decision taken

Free format text: JAPANESE INTERMEDIATE CODE: C03

Effective date: 20230110

C30A Notification sent

Free format text: JAPANESE INTERMEDIATE CODE: C3012

Effective date: 20230110

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230201

R150 Certificate of patent or registration of utility model

Ref document number: 7220986

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250